Brian Daniel Webster Sells 15,000 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Key Points

• Insider sale: Brian Daniel Webster sold 15,000 Kestra Medical Technologies shares for approximately $412,200, reducing his ownership by 3.16% to 460,215 shares. He has also sold additional shares in several transactions since late July.
• Stock and financial performance: KMTS traded near $27.93, close to its 52-week high of $30.00, but the company reported a quarterly EPS loss of $0.67, missing estimates, alongside a negative net margin of 138.35%.
• Analyst outlook: Ratings are mixed, with four Buy, two Hold, and one Sell recommendations; the consensus rating is Hold with a $28.14 target price. BTIG raised its target to $32, while JPMorgan initiated coverage with an Overweight rating and a $30 target.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $27.48, for a total value of $412,200.00. Following the completion of the transaction, the insider directly owned 460,215 shares in the company, valued at approximately $12,646,708.20. This trade represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Tuesday, August 4th, Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.52, for a total transaction of $1,272,588.00.
• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.92, for a total transaction of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total transaction of $202,224.80.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total transaction of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00.

Kestra Medical Technologies Stock Performance

KMTS traded up $0.11 during midday trading on Tuesday, hitting $27.93. The company had a trading volume of 249,303 shares, compared to its average volume of 324,989. The stock's 50 day moving average price is $24.13 and its 200 day moving average price is $22.74. Kestra Medical Technologies, Ltd. has a 52 week low of $15.42 and a 52 week high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. As a group, analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on KMTS shares. Weiss Ratings upgraded Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. BTIG Research boosted their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a report on Monday, August 10th. They set an "overweight" rating and a $30.00 price objective on the stock. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a "market perform" rating for the company. Finally, Wall Street Zen raised shares of Kestra Medical Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $28.14.

Hedge Funds Weigh In On Kestra Medical Technologies

Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its holdings in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock worth $74,000 after purchasing an additional 656 shares in the last quarter. Rhumbline Advisers increased its stake in Kestra Medical Technologies by 7.3% in the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company's stock valued at $307,000 after buying an additional 874 shares during the last quarter. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $31,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company's stock worth $144,000 after buying an additional 1,392 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source